Spexis AG / Key word(s): Miscellaneous 29-Nov-2023 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.   Ad hoc announcement pursuant to Art. 53 LR   Spexis Provides Update Regarding Debt-Restructuring Moratorium Allschwil, Switzerland, November 29, 2023 Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it is in discussions with SPRIM Global Investments (“SGI”) to restructure its curren ..read more

Issuer: Mainz BioMed N.V. / Key word(s): Conference 29.11.2023 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast BERKELEY, US – MAINZ, Germany – NOVEMBER 29, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that its presentation at the 35th Annual Piper Sandler Healthcare Conference, to be delivered by Chief Executive ..read more

Heidelberg Pharma AG / Key word(s): Personnel Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board 29-Nov-2023 / 11:56 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Announces Changes to the Executive Management Board Ladenburg, Germany, 29 November 2023 ..read more

Kuros Biosciences AG / Key word(s): Regulatory Approval Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages 28.11.2023 / 18:00 CET/CEST MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interbody use MagnetOs can now be used on-label in any interbody cage cleared for use with a bone void filler The exceptional handling properties of MagnetOs Flex Matrix are uniquely applicable to interbody applications Schlieren (Zurich), Switzerland, November 28, 2023 – Kuros Biosciences (“Kuros” or the ..read more

EQS-News: Gerresheimer AG / Key word(s): ESG Gerresheimer: Green electricity from wind for German production sites 28.11.2023 / 10:25 CET/CEST The issuer is solely responsible for the content of this announcement. Gerresheimer: Green electricity from wind for German production sites Agreement signed with PNE AG to supply around 35 GWh per year CO2 emissions to be cut by around 18,000 t Gerresheimer increases share of green power in energy supply Goal for 2030: 100 % electricity from renewable sources Düsseldorf, Germany, November 28, 2023. Gerresheimer, the innovative system and sol ..read more

EQS-News: Biotest AG / Key word(s): Research Update Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation 28.11.2023 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE    Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation   Trimodulin is a globally unique, innovative human plasma protein preparation in advanced development for treatment of pneumoni ..read more

Edison Investment Research Limited Edison issues update on The European Smaller Companies Trust (ESCT): Top of the peer group over short and long term. 21-Nov-2023 / 17:12 GMT/BST The issuer is solely responsible for the content of this announcement.   London, UK, 21 November 2023   Edison issues update on The European Smaller Companies Trust (ESCT): Top of the peer group over short and long term The European Smaller Companies Trust’s (ESCT’s) manager, Ollie Beckett at Janus Hendersons Investors (JHI), remains very positive about the outlook for European small-cap companies, whic ..read more

Vita 34 AG / Key word(s): Capital Increase Vita 34 AG: resolves on cash capital increase under exclusion of subscription rights in the amount of up to 10% of the share capital, commitments from investors 27-Nov-2023 / 11:37 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.   THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA ..read more

Edison Investment Research Limited Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX 27-Nov-2023 / 08:53 GMT/BST The issuer is solely responsible for the content of this announcement.   London, UK, 27 November 2023   Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX ReNeuron has announced its H124 results (to end-September 2023), reaffirming its commitment to advance CustomEX, its proprietary stem cell-derived exosome delivery platform. The key operational update from the period included in vivo data, marki ..read more

EQS-News: Formycon AG / Key word(s): Regulatory Admission Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept) 27.11.2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // November 27, 2023   Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)   Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Klinge Biopharma GmbH (Klinge) announce that the marketing authorization application (MAA) for FYB203, a biosimilar candidate ..read more